A randomized double-blind phase II study of the Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least 4 cycles of platinum-based chemotherapy: NCCTG (Alliance) N0923 Study
- Citation:
- J Thorac Oncol vol 15 (1) 110-119
- Year:
- 2020
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 9
- Parents:
- 960
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Neotropix, Inc
- Grants:
- U10CA180821, U10CA180882, U10CA180866, U10CA180790, U10CA180791, U10CA233196, U10CA233290, U10CA180820, UG1CA189952, U10CA180888
- Corr. Author:
- Authors:
- Erin L. Schenk Sumithra J. Mandrekar Grace K. Dy Marie Christine Aubry Angelina D. Tan Shaker R. Dakhil Bradley A. Sachs Jorge J. Nieva Erin Bertino Christine Lee Hann Steven E. Schild Troy W. Wadsworth Alex A. Adjei Julian R. Molina
- Networks:
- CA011, KS055, LAPS-CO070, LAPS-MD017, LAPS-MN026, LAPS-NY158, OH008, WA030
- Study
- NCCTG-N0923
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Small cell lung cancer, virotherapy, NTX-010